Antigen discovery for the development of cancer immunotherapy
Author:
Publisher
Elsevier BV
Subject
Immunology,Immunology and Allergy
Reference209 articles.
1. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs;Haslam;JAMA Netw. Open,2019
2. A guide to cancer immunotherapy: from T cell basic science to clinical practice;Waldman;Nat. Rev. Immunol.,2020
3. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways;Kraehenbuehl;Nat. Rev. Clin. Oncol.,2022
4. Understanding the tumor immune microenvironment (TIME) for effective therapy;Binnewies;Nat. Med.,2018
5. An immunogenic personal neoantigen vaccine for patients with melanoma;Ott;Nature,2017
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapy;Clinical and Translational Medicine;2024-09
2. Advances in antitumor application of ROS enzyme-mimetic catalysts;Nanoscale;2024
3. Investigative needle core biopsies for multi-omics in Glioblastoma;2023-12-31
4. The SysteMHC Atlas v2.0, an updated resource for mass spectrometry-based immunopeptidomics;Nucleic Acids Research;2023-11-24
5. Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?;Neuro-Oncology;2023-11-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3